Oragenics, Inc. (NYSE American: OGEN) shares +44.03% to $8860 rocked in the morning session Thursday as it announced that it had entered an agreement with Adjuvance Technologies Inc. for the use of adjuvant TQL1055 in the Terra CoV-2 vaccine against COVID-19. The adjuvants that vaccines are prepared with are added to enhance their immunogenicity. The TQL1055 is a novel, semisynthetic analog of the saponin adjuvant QS-21 with improved stability and manufacturing efficiency.
The preliminary agreement calls for the use of TQL1055 in pre-clinical animal studies supporting the FDA Investigational New Drug application likely to occur mid-2021, with the possibility of entering into a licensing deal for human clinical trials later in the year.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Tests will be conducted on hamsters and mice to assess the vaccine’s immunogenicity, and an IND filing will require a study on rodents to assess toxicology.
Dr. Tyler Martin, Chief Executive Officer of Adjuvance Technologies, noted, “We are delighted to be partnering with Oragenics and believe that our adjuvant, TQL1055, will provide the increased immune response necessary for a successful and widely available coronavirus vaccine.”
